Open AccessDiscordance in Biomarker Expression in Breast Cancer After Metastasis: Single Center Experience in India
Author(s) -
Ajay Gogia,
Svs Deo,
Dayanand Sharma,
R.K. Phulia,
Sanjay Thulkar,
Prabhat Singh Malik,
Sandeep Mathur
Publication year - 2019
Publication title -
journal of global oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.002
H-Index - 17
ISSN - 2378-9506
DOI - 10.1200/jgo.18.00184
Subject(s) - medicine , breast cancer , biomarker , oncology , estrogen receptor , cancer , metastasis , progesterone receptor , cohort , lung cancer , triple negative breast cancer , brain metastasis , biochemistry , chemistry
Biomarker-estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/ neu) -discordance plays an essential role in the management and prognosis of patients with metastatic breast cancer. Rates of discordance have been previously reported around 12% to 35%, 30% to 50%, and 5% to 15%, respectively, in Western literature. Data are sparse regarding the same from developing countries, such as India.